PBF 999

Drug Profile

PBF 999

Alternative Names: PBF-999

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Palobiofarma
  • Developer Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Palobiofarma
  • Class Antipsychotics
  • Mechanism of Action Adenosine A2A receptor antagonists; Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Discontinued Huntington's disease

Most Recent Events

  • 20 Oct 2017 Discontinued - Phase-I for Huntington's disease (In volunteers) in Spain (PO) (Palobiofarma pipeline, October 2017)
  • 20 Oct 2017 Phase-I clinical trials in Cancer (unspecified route) before October 2017 (Palobiofarma pipeline, October 2017)
  • 25 Sep 2014 Phase-I clinical trials in Huntington's disease (In volunteers) in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top